Drug name - Reclast
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8052987 | NOVARTIS | Method of administering bisphosphonates |
Oct, 2023
(1 year, 27 days from now) | |
| US7932241 | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Feb, 2028
(5 years from now) | |
|
US7932241
(Pediatric) | NOVARTIS | Pharmaceutical products comprising bisphosphonates |
Aug, 2028
(5 years from now) | |
Drugs and Companies using ZOLEDRONIC ACID ingredient
Treatment: Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis
Dosage: INJECTABLE;INTRAVENOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 5MG BASE/100ML | INJECTABLE;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.